866-997-4948(US-Canada Toll Free)

Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2024

Published By :

Transparency

Published Date : Apr 2017

Category :

Biotechnology

No. of Pages : 176 Pages

Global Human Microbiome Market: Overview

The human microbiome also known as microbiota is composed of population of microbes such as fungi, bacteria and archaea. These microbes reside on the surface or in the deep layers of skin in oral mucosa, the saliva, gastrointestinal tracts and in the conjunctiva. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and contributing to digestion of food.

Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand the factors regulating microbial colonization in areas of the body that are just millimeters apart. The Human Microbiome Project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated with a goal of identifying and characterizing the microbes found within the healthy and diseases human body.

Global Human Microbiome Market: Scope of the Study

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for microbiome therapeutics is segmented based on therapeutic area and region, while the market for microbiome diagnostics is segmented on the basis of indication, technology and region.

It comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2024 for diagnostics and 2020 to 2024 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/20 to 2024 are provided for all the segments.

Market related factors such as new product launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global human microbiome market have been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Human Microbiome Market: Segmentation

Based on indication, the global human microbiome diagnostics market has been segmented into Gastrointestinal and Metabolic disorders, Womens Health, Cancer and Others. Gastrointestinal & metabolic disorders are likely to show most promising growth in the market owing to the higher unmet medical need for gut health disorders as well as a rise in population suffering from faulty- lifestyle based metabolic diseases.

Based on technology, the market has been segmented into 16s rRNA sequencing and metagenomic sequencing. Both the forms have been documented to have various advantages with regard to accurate testing and hence, both these segments garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into Gastrointestinal Disorders, Metabolic disorders, Womens Health, Skin Disorders and Others. Other therapeutic areas include autoimmune disorders, infant health disorders, and rare diseases.

Geographically, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the human microbiome market.

Companies Mentioned in the Study

The report profiles major players in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel Inc., Seres Therapeutics, Second Genome, uBiome Inc., Metabiomics Corp., Rebiotix Inc., Vedanta Biosciences etc.

The global human microbiome market has been segmented as follows:

By Indication

  • Gastrointestinal and Metabolic Disorders
  • Womens Health
  • Cancer
  • Others

By Technology

  • 16s rRNA Sequencing
  • Metagenomic Sequencing

By Therapeutic Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Womens Health
  • Skin Disorders
  • Others

By Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • UAE
  • South Africa
  • Rest of Middle East and Africa

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Human Microbiome Market

Chapter 4. Market Overview

4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Human Microbiome Market Analysis and Forecasts
4.4.1. Global Human Microbiome Diagnostics Market Analysis and Forecast, 2018-2024
4.4.2. Global Human Microbiome Therapeutics Market Analysis and Forecast, 2020-2024
4.5. Global Human Microbiome Market Outlook
4.6. Human Microbiome Therapeutics : Pipeline Overview

Chapter 5. Global Human Microbiome Diagnostics Market Analysis and Forecasts, By Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Gastrointestinal and Metabolic Disorders
5.3.2. Womens Health
5.3.3. Cancer
5.3.4. Others
5.4. Market Attractiveness Analysis, by Indication, 2018
5.5. Key Trends

Chapter 6. Global Human Microbiome Diagnostics Market Analysis and Forecasts, By Technology
6.1. Introduction
6.2. Market Size (US$ Mn) Forecast, by Technology
6.2.1. 16s rRNA Sequencing
6.2.2. Metagenomic Sequencing
6.3. Market Attractiveness Analysis, by Technology, 2018
6.4. Key Developments

Chapter 7. Global Human Microbiome Therapeutics Market Analysis and Forecasts, By Therapeutic Area
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Therapeutic Area
7.3.1. Gastrointestinal Disorders
7.3.2. Metabolic Disorders
7.3.3. Womens Health
7.3.4. Skin Disorders
7.3.5. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area, 2020
7.5. Key Trends

Chapter 8. Global Human Microbiome Market Analysis and Forecasts, By Region
8.1. Introduction
8.2. Market Size (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region,
8.3.1. Global Human Microbiome Diagnostics Market (2018)
8.3.2. Global Human Microbiome Therapeutics Market (2020)

Chapter 9. North America Human Microbiome Market Analysis and Forecast
9.1. Introduction
9.2. Market Size (US$ Mn) Forecast, by Indication
9.2.1. Gastrointestinal and Metabolic Disorders
9.2.2. Womens Health
9.2.3. Cancer
9.2.4. Others
9.3. Market Size (US$ Mn) Forecast, by Technology
9.3.1. 16s rRNA Sequencing
9.3.2. Metagenomic Sequencing
9.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
9.4.1. Gastrointestinal Disorders
9.4.2. Metabolic Disorders
9.4.3. Womens Health
9.4.4. Skin Disorders
9.4.5. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis, by Indication, 2018
9.7. Market Attractiveness Analysis, by Technology, 2018
9.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
9.9. Key Trends

Chapter 10. Europe Human Microbiome Market Analysis and Forecast
10.1. Introduction
10.2. Market Size (US$ Mn) Forecast, by Indication
10.2.1. Gastrointestinal and Metabolic Disorders
10.2.2. Womens Health
10.2.3. Cancer
10.2.4. Others
10.3. Market Size (US$ Mn) Forecast, by Technology
10.3.1. 16s rRNA Sequencing
10.3.2. Metagenomic Sequencing
10.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
10.4.1. Gastrointestinal Disorders
10.4.2. Metabolic Disorders
10.4.3. Womens Health
10.4.4. Skin Disorders
10.4.5. Others
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. U.K.
10.5.2. Germany
10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis, by Indication, 2018
10.7. Market Attractiveness Analysis, by Technology, 2018
10.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
10.9. Key Trends

Chapter 11. Asia Pacific Human Microbiome Market Analysis and Forecast
11.1. Introduction
11.2. Market Size (US$ Mn) Forecast, by Indication
11.2.1. Gastrointestinal and Metabolic Disorders
11.2.2. Womens Health
11.2.3. Cancer
11.2.4. Others
11.3. Market Size (US$ Mn) Forecast, by Technology
11.3.1. 16s rRNA Sequencing
11.3.2. Metagenomic Sequencing
11.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
11.4.1. Gastrointestinal Disorders
11.4.2. Metabolic Disorders
11.4.3. Womens Health
11.4.4. Skin Disorders
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. China
11.5.2. Japan
11.5.3. Rest of Asia Pacific
11.6. Market Attractiveness Analysis, by Indication, 2018
11.7. Market Attractiveness Analysis, by Technology, 2018
11.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
11.9. Key Trends

Chapter 12. Latin America Human Microbiome Market Analysis and Forecast
12.1. Introduction
12.2. Market Size (US$ Mn) Forecast, by Indication
12.2.1. Gastrointestinal and Metabolic Disorders
12.2.2. Womens Health
12.2.3. Cancer
12.2.4. Others
12.3. Market Size (US$ Mn) Forecast, by Technology
12.3.1. 16s rRNA Sequencing
12.3.2. Metagenomic Sequencing
12.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
12.4.1. Gastrointestinal Disorders
12.4.2. Metabolic Disorders
12.4.3. Womens Health
12.4.4. Skin Disorders
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis, by Indication, 2018
12.7. Market Attractiveness Analysis, by Technology, 2018
12.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
12.9. Key Trends

Chapter 13. Middle East & Africa Human Microbiome Market Analysis and Forecast
13.1. Introduction
13.2. Market Size (US$ Mn) Forecast, by Indication
13.2.1. Gastrointestinal and Metabolic Disorders
13.2.2. Womens Health
13.2.3. Cancer
13.2.4. Others
13.3. Market Size (US$ Mn) Forecast, by Technology
13.3.1. 16s rRNA Sequencing
13.3.2. Metagenomic Sequencing
13.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
13.4.1. Gastrointestinal Disorders
13.4.2. Metabolic Disorders
13.4.3. Womens Health
13.4.4. Skin Disorders
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Country
13.5.1. UAE
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis, by Indication, 2018
13.7. Market Attractiveness Analysis, by Technology, 2018
13.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
13.9. Key Trends

Chapter 14. Competition Landscape
14.1. Company Profiles
14.1.1. AO Biome LLC
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.1.2. Recent Developments
14.1.1.3. Product Portfolio
14.1.1.4. SWOT Analysis
14.1.1.5. Strategic Overview
14.1.2. Enterome Biosciences SA
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.2.2. Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Metabiomics Corp.
14.1.3.1. Company Overview (HQ, business segments, employee strength)
14.1.3.2. Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Recent Developments
14.1.3.5. Strategic Overview
14.1.4. MicroBiome Therapeutics LLC
14.1.4.1. Company Overview (HQ, business segments, employee strength)
14.1.4.2. Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Recent Developments
14.1.5. Osel, Inc.
14.1.5.1. Company Overview (HQ, business segments, employee strength)
14.1.5.2. Clinical Trial Candidates
14.1.5.3. Product Portfolio
14.1.5.4. SWOT Analysis
14.1.5.5. Strategic Overview
14.1.6. Rebiotix, Inc.
14.1.6.1. Company Overview (HQ, business segments, employee strength)
14.1.6.2. Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Recent Developments
14.1.6.5. Strategic Overview
14.1.7. uBiome, Inc.
14.1.7.1. Company Overview (HQ, business segments, employee strength)
14.1.7.2. Recent Developments
14.1.7.3. Product Portfolio
14.1.7.4. SWOT Analysis
14.1.7.5. Strategic Overview
14.1.8. Second Genome
14.1.8.1. Company Overview (HQ, business segments, employee strength)
14.1.8.2. Financial Overview: Funding and Investments
14.1.8.3. Product Portfolio
14.1.8.4. SWOT Analysis
14.1.8.5. Strategic Overview
14.1.9. Seres Therapeutics
14.1.9.1. Company Overview (HQ, business segments, employee strength)
14.1.9.2. Product Portfolio
14.1.9.3. Financial Overview
14.1.9.4. SWOT Analysis
14.1.9.5. Strategic Overview
14.1.10. Synthetic Biologics, Inc.
14.1.10.1. Company Overview (HQ, business segments, employee strength)
14.1.10.2. Product Portfolio
14.1.10.3. Financial Overview
14.1.10.4. SWOT Analysis
14.1.10.5. Strategic Overview
14.1.11. Vedanta Biosciences
14.1.11.1. Company Overview (HQ, business segments, employee strength)
14.1.11.2. Product Portfolio
14.1.11.3. Recent Developments
14.1.11.4. SWOT Analysis
14.1.11.5. Strategic Overview
14.1.12. Others
14.1.12.1. Metabogen AB
14.1.12.2. Becton Dickinson & Company
14.1.12.3. Evelo Biosciences
14.1.12.4. ARTPred
14.1.12.5. MaaT Pharma
14.1.12.6. Blue Turtle Bio Technologies
14.1.12.7. Axial Therapeutics
14.1.12.8. Whole Biome
14.1.12.9. 4D Pharma
14.1.12.10. Symbiotix Therapies
14.1.12.11. Phi Therapeutics
14.1.12.12. Synlogic
14.1.12.13. Biospherex LLC

List of Table

Table 1: Pipeline Scenario
Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 20182024
Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 20182024
Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 20202024
Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region
Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region
Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 20182024
Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 20182024
Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 20182024
Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 20202024
Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 20202024
Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 20182024
Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 20182024
Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 20182024
Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 20202024
Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 20202024
Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 20182024
Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 20182024
Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 20182024
Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 20202024
Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 20202024
Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 20182024
Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 20182024
Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 20182024
Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area,
Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 20202024
Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication,
Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology,
Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 20182024
Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 20202024
Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country

List of Chart

Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 3: Human Microbiome Diagnostic Market Value Share By Indication (2018)
Figure 4: Human Microbiome Diagnostic Market Value Share By Technology (2018)
Figure 5: Human Microbiome Therapeutics Market Value Share By Therapeutic Area (2020)
Figure 6: Human Microbiome Therapeutics Market Value Share By Region (2020)
Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 9: Global Womens Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2018
Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2018
Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 20182024
Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 20202024
Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 20202024
Figure 20: Global Womens Health Market Size (US$ Mn) and Y-o-Y Growth (%), 20202024
Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 20202024
Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 20202024
Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2024
Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2018 and 2024
Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2020
Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2018
Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 35: North America Therapeutics Market Value Share Analysis By Therapeutic Area, 2020 and 2024
Figure 36: North America Therapeutics Market Value Share Analysis By Country, 2020 and 2024
Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 46: Europe Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 48: Europe Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country
Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country
Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2018 and 2024
Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2018 and 2024
Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country, 2018 and 2024
Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2018 and 2024
Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2018 and 2024
Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country, 2018 and 2024
Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 20182024
Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 20202024
Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2018 and 2024
Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2018 and 2024
Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country, 2018 and 2024
Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2024
Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country, 2020 and 2024
Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *